Unique ID issued by UMIN | UMIN000037620 |
---|---|
Receipt number | R000042891 |
Scientific Title | A study on the effect of Lactobacillus brevis KB290 (heat-killed) on Visceral Fat. |
Date of disclosure of the study information | 2019/08/24 |
Last modified on | 2020/02/05 15:27:35 |
A study on the effect of LAB (heat-killed) on Visceral Fat.
A study on the effect of LAB (heat-killed) on Visceral Fat.
A study on the effect of Lactobacillus brevis KB290 (heat-killed) on Visceral Fat.
A study on the effect of Lactobacillus brevis KB290 (heat-killed) on Visceral Fat.
Japan |
No
Adult |
Others
NO
To investigate the effect of Lactobacillus brevis KB290 (heat-killed) on Visceral Fat reduction.
Efficacy
Visceral fat area
Abdominal subcutaneous fat area, total fat area, body weight (BMI), blood pressure, body fat percentage, muscle mass, waist/hip circumference, AST (GOT), ALT (GPT), gamma-GTP, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, blood glucose level, insulin, HbA1c, HOMA-IR, fecal microbiota.
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
No need to know
3
Treatment
Food |
A beverage not containing heat-killed Labre per day for 12 weeks.
A beverage containing heat-killed Labre (low-dose) per day for 12 weeks.
A beverage containing heat-killed Labre (high-dose) per day for 12 weeks.
20 | years-old | <= |
65 | years-old | > |
Male and Female
(1)Japanese male and female aged 20 to 64 years-old at acquisition of the consent.
(2)Whose BMI are 23 or more and less than 30 at screening test.
(3)Who can make self-judgment, voluntarily agreed to participate to this study, and provide written informed consent.
(1)Who use medicines that may affect obesity, hyperlipidemia, lipid metabolism.
(2)Who has such serious diseases as liver disease, cardiovascular disease, respiratory disease, endocrine disorder, metabolic disease, food allergy disease.
(3)Who cannot stop intake health foods or supplements which may affect obesity, hyperlipidemia, lipid metabolism, during this study.
(4)Who has a current or history of drug dependence and/or alcoholism.
(5)Who has been implanted metal in the DUAL SCAN measurement site.
(6)Who has implantable medical devices (e.g., cardiac pacemaker and/or implantable defibrillator).
(7)Who has been diagnosed as familial hyperlipidemia.
(8)Who is pregnant or breast-feeding or willing to be pregnant during this study.
(9)Who has an irregular diet, and/or is shift worker and/or midnight-shift worker.
(10)Who is planning to participate and/or has participated in other clinical studies.
(11)Who is judged as unsuitable for this study by the principal investigator.
120
1st name | Shigenori |
Middle name | |
Last name | Suzuki |
Kagome Co., Ltd.
Innovation Division
329-2762
17 Nishitomiyama, Nasushiobarashi, Tochigi, 329-2762, Japan
0287-36-2935
Shigenori_Suzuki@kagome.co.jp
1st name | Yoshika |
Middle name | |
Last name | Komori |
KSO Corporation
Sales department
105-0014
1-9-7 Shibaura, Minato-ku, Tokyo
03-3452-7733
yoshi@kso.co.jp
Kagome Co., Ltd.
None
Self funding
KSO Corporation
Kagome Ethics Committee
3-21-1, F tower, Hamacho, Nihonbashi, Tyuo-ku, Tokyo, Japan
03-5623-8501
Takuji_Hayakawa@kagome.co.jp
NO
2019 | Year | 08 | Month | 24 | Day |
Unpublished
Completed
2019 | Year | 07 | Month | 18 | Day |
2019 | Year | 07 | Month | 19 | Day |
2019 | Year | 08 | Month | 24 | Day |
2019 | Year | 12 | Month | 08 | Day |
2019 | Year | 08 | Month | 07 | Day |
2020 | Year | 02 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042891